LatestIPODiscovery,2025Year12Month24On a certain day, the Shenzhen Stock Exchange (SZSE) official website showed that BrosMed Medical Co., Ltd. (referred to as BrosMed Medical) was listed on the Growth Enterprise Market (GEM).IPOApplication Accepted，The sponsor institution is China International Capital Corporation Limited, the auditing institution is Rongcheng Certified Public Accountants (Special General Partnership), and the law firm is Beijing Guofeng Law Firm.

LatestIPOWill continue to pay attention to BrosMed MedicalIPOProgress!

BrosMed Medical focuses on the research, development, production, and global sales of high-performance vascular interventional medical devices. It is a leading provider of complex vascular disease interventional treatment solutions in the global industry and also a leading R&D and manufacturing enterprise in China in terms of production and sales volume of vascular interventional balloon catheters.

In terms of product system construction, the company has formed a comprehensive product matrix covering multiple treatment scenarios, possessing50More than 10 product series, covering key areas such as coronary intervention, peripheral intervention, neurointervention, hemodialysis access, and interventional accessories. These include core product lines such as various general balloon catheters, functional balloon catheters, drug-coated balloon catheters, interventional guidewires and catheters, multiple thrombectomy devices, calcification treatment devices, and energy-based therapeutic devices, fully meeting the diverse clinical needs for the interventional treatment of complex vascular diseases.

In terms of R&D and production layout, the company emphasizes global resource integration and production capacity assurance, and has currently established operations globally.5R&D centers and laboratories, continuously driving the iteration of core technologies and the development of innovative products; establishing4A production base to ensure the scaled and high-quality supply of products; at the same time, establish3An international operations center, providing efficient operational support and service assurance for global market expansion.

In terms of market coverage, the company's products have been successfully marketed both domestically and internationally.100countries and regions, serving over ten thousand hospitals and medical centers worldwide. With stable product performance, systematic treatment solutions, and professional technical support, BrosMed Medical has established a strong brand image in the domestic and international vascular interventional medical device markets, gradually building up a global market presence and customer service network.

The company has long been practicing“Innovation+Scaling+Internationalization”The "Three-in-One" business development strategy has grown into a rapidly developing multinational platform enterprise in the global vascular intervention industry, with significant industry influence.“Empower Chinese Innovation, Benefit Patients Worldwide”It is also the core development concept of the company's scientific and technological innovation and global industrialization. Since its establishment, the company has continuously maintained high-intensity R&D investment, building a well-structured and highly efficient R&D talent team.IPDThe product R&D system relies on the Guangdong Provincial Vascular Intervention Technology and Device Engineering Research Center, Dongguan Key Laboratory for Research and Development of Vascular Intervention Medical Devices,CNASCore research carriers such as laboratories have achieved multiple global breakthroughs in product technology, core processes, and other fields through industry-university-research cooperation and medical-engineering innovation collaboration on a global scale. As of the date of the signing of the prospectus, the company has gone public.7A product that is a global first or possesses unique innovative technology; at the same time, the company, as the sole completing entity, was honored with2020The Second Prize of Guangdong Provincial Science and Technology Progress Award12The product has been recognized as a prestigious high-tech product in Guangdong Province, with more than X authorized domestic and international invention patents.80Item, laying a solid foundation for continuous innovation.

BrosMed Medical, as a leading medical technology innovation platform enterprise in the field of complex vascular interventional therapy, excelling in innovation, technology, scale, and globalization, has maintained a long-term stable and rapid growth trend in both domestic and overseas markets since commencing sales.2022-2024The average annual compound growth rate of annual operating revenue reached48.98%, is a company with long-term high growth potential in the global vascular interventional industry. The company has established international operation centers in China, Europe, and the United States, and has set up local marketing offices in multiple countries and regions, providing efficient and professional services to global customers and partners; it has currently expanded to over100Build a long-term stable marketing channel system in countries and regions, with overseas cooperative distributors exceeding200Home, domestic cooperative distributors near800Home, serving over ten thousand hospitals and medical centers.

BrosMed Medical has a comprehensive qualification and honor system, and is a national high-tech enterprise and a national specialized, refined, novel enterprise.“Key Little Giant”The enterprise has been awarded the title of Guangdong Province's Single-item Champion in Manufacturing, one of Dongguan City's Top 100 Innovative Enterprises, and a Doubling Enterprise of Dongguan City. It has also won the Gold Award at the first Guangdong-Hong Kong-Macao Greater Bay Area (Guangdong) High-value Trademark Brand Cultivation Competition and the Grand Prize at the first Dongguan Science and Technology Innovation and Entrepreneurship Competition, among others. Additionally, the company has repeatedly ranked on authoritative industry lists, including the China Innovative Medical Device List.100Strong, Chinese Innovative Enterprises150Strong (Qingke Ranking), etc.

During the reporting period, the composition of the company's main business by product is as follows: